A calculator to help men and their doctors assess the risk of prostate cancer has had a major upgrade to enhance men's and their physicians' understanding of a man's risk of prostate cancer.
Men without prostate cancer taking part in the trial who participate in other aspects are most likely to undergo a challenging biopsy.
Prostate-specific antigen (PSA) screening is associated with a lasting reduction in prostate cancer mortality, according to a study published online.
A genomic tool can help doctors and patients make a more informed decision on the need for radiation therapy after surgery for prostate cancer.
Men with diagnosed depressive disorders are less likely to pursue definitive treatment options for prostate cancer and more likely to have poorer outcomes.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|